Quintiles may look at takeovers and strategic deals

By Gareth Macdonald

- Last updated on GMT

Related tags: Analyst david windley, Finance

The US contract research organization (CRO) Quintiles may look at acquisitions and more ‘strategic partnerships’ after securing a $2.43bn credit facility.

The firm announced the move, which includes a $225m credit facility and a $2.2bn loan due in 2018, and explained that: “Current financing terms are attractive, and banks are looking to invest in the right companies​.”

A Quintiles spokeswoman told Outsourcing-pharma.com that, in addition to repaying debt, proceeds will be used for corporate actions that “could include acquisitions, strategic alliances with customers that include a capital investment, share repurchase or a shareholder dividend​.”

The news follows just weeks after Quintiles formed a strategic​ partnership with Takeda, under which it will support all of the Japanese drugmaker’s development programmes aside from those focused on oncology.

Quintiles also recently entered a long-term partnership with South Korean conglomerate Samsung as part of the latter’s effort to move into the biomanufacturing sector.

The plan is to set up a manufacturing facility with Samsung investing $266m and Quintiles putting in an initial some of $30m and providing research and consulting services on all aspects of the drug industry.

Acquisitions

But, while Quintiles’ comments about partnering were of interest, much media attention has focused on its reference to acquisitions with some, like Jefferies & Co analyst David Windley, speculating the firm will invest in early-stage capacity.

He told News & Observer that: “an acquisition is in early-stage drug development would help Quintiles compete for new contracts with large, publicly traded rivals such as Covance of New Jersey​.”

Related news

Show more

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 01-Jun-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

How a clinical metadata repository helps with data

How a clinical metadata repository helps with data

Formedix | 22-Mar-2021 | Technical / White Paper

This article covers the various ways a clinical metadata repository helps with data quality, and in turn, with data quality in the clinical trials process....

Related suppliers

Follow us

Products

View more

Webinars